Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.99 | N/A | +8.08% |
management commentary, guidance changes, and full analysis available with Pro.
| +8.08% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
Gilead Sciences reported an EPS that exceeded expectations, indicating strong performance in that area. However, the lack of revenue data and guidance may leave investors uncertain about future growth. The stock reaction was neutral, suggesting that investors are taking a wait-and-see approach following this report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BAIDU INC A ADR
Jul 23, 2012